For women undergoing IVF, the most dangerous moment isn’t the retrieval or the transfer. It’s the trigger shot — the injection that tells your ovaries to release mature eggs. Standard triggers (hCG) can cause ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening complication. Kisspeptin may eliminate that risk entirely.
Kisspeptin is a neuropeptide that sits at the top of the reproductive hormone cascade. It activates KISS1R receptors on hypothalamic GnRH neurons, triggering the downstream release of LH and FSH that drives ovulation. It was first administered to healthy men in 2005 and to women in 2007, where researchers discovered something remarkable: the LH response was dramatically stronger during the preovulatory phase of the menstrual cycle, producing surges consistent with the natural ovulatory trigger.
This meant kisspeptin could potentially replace hCG as the IVF trigger — stimulating natural-pathway ovulation instead of forcing it through an artificial hormone surge.
In 2014, researchers at Hammersmith Hospital London published the first clinical trial using kisspeptin-54 to trigger oocyte maturation during IVF. In 53 subfertile women, a single subcutaneous injection of kisspeptin-54 successfully induced egg maturation. Fertilization and embryo transfer occurred in 92% of patients (49/53). Biochemical pregnancy rate was 40% and clinical pregnancy rate was 23%.
A subsequent Phase 2 trial with 60 women specifically at high risk of OHSS confirmed oocyte maturation in 95% of women. At the optimal dose (9.6 nmol/kg), oocyte yield reached 121%. And the critical finding: zero cases of OHSS across all kisspeptin-treated patients.
Pregnancy rates with kisspeptin ranged between 23-37% across randomized trials — comparable to or enhanced versus traditional gonadotropin protocols, but without the life-threatening risk of OHSS.
OHSS causes fluid to leak from overstimulated ovaries into the abdomen and chest. In severe cases it can cause blood clots, kidney failure, and death. Women with PCOS are at particularly high risk because they tend to produce a large number of follicles in response to stimulation drugs. Kisspeptin’s natural-pathway trigger avoids the sustained ovarian stimulation that causes OHSS, making it especially relevant for the PCOS population — which represents roughly 1 in 10 women of reproductive age.
Native kisspeptin-54 has a short half-life requiring precise injection timing. MVT-602, a kisspeptin receptor agonist developed by Myovant Sciences, is designed to provide a longer-acting signal. In clinical studies with healthy premenopausal women, MVT-602 induced ovulation in 75-100% of participants depending on dose. This analog could make kisspeptin-based IVF triggers more practical for widespread clinical use.
Kisspeptin is also being investigated for hypothalamic amenorrhea — the loss of periods due to stress, low body weight, or excessive exercise. Women with hypothalamic amenorrhea have suppressed GnRH pulsatility. Kisspeptin, as the upstream activator of GnRH, can potentially restart the reproductive cascade without the risks of exogenous gonadotropins.
Kisspeptin is being researched primarily as an IVF trigger to replace hCG, reducing OHSS risk. It's also being investigated for hypothalamic amenorrhea (absent periods due to stress or low body weight). It is not currently available as a take-home fertility treatment and has not been studied for general fertility enhancement outside of clinical trials.
Clinical trials to date show zero cases of OHSS with kisspeptin triggers, compared to significant OHSS rates with hCG (especially in women with PCOS). However, the total number of women studied is still relatively small. Larger trials are ongoing to confirm these safety advantages.
Kisspeptin for fertility is only available through enrollment in clinical trials. It is not FDA-approved for any reproductive indication. Research peptide vendors sell kisspeptin-10, but these products are not intended for fertility use and are not the same formulation (kisspeptin-54) used in the IVF trials.
No. Clomid and letrozole are oral ovulation-induction drugs that work by blocking estrogen receptors (Clomid) or inhibiting estrogen production (letrozole), causing the pituitary to release more FSH. Kisspeptin works upstream of all of these, activating GnRH neurons directly. It's a fundamentally different mechanism with a different risk profile.